FDA Rejects Vanda's Hetlioz for Jet Lag—Shares Drop 12%
Vanda Pharmaceuticals stock falls in premarket trading after FDA denies Hetlioz approval for jet lag disorder, citing clinical trial design concerns despite positive efficacy data.
/ 12 items
#VNDA↓
Vanda Pharmaceuticals Stock Soars on FDA Approval of Motion Sickness Drug
Vanda Pharmaceuticals shares jump 19% in premarket trading after FDA approves Nereus, the first new motion sickness treatment in 40 years.
Vanda Submits Application for New GPP Treatment
Vanda Pharmaceuticals files FDA application for imsidolimab, a promising new treatment for generalized pustular psoriasis, with potential approval by mid-2026.
FDA Clears Vanda's Tradipitant for Motion Sickness Studies
The FDA has lifted a study restriction on Vanda Pharmaceuticals' Tradipitant, potentially making it the first new motion sickness drug in decades.
Vanda's Motion Sickness Drug Faces More Delays
Vanda Pharmaceuticals' (VNDA) tradipitant approval delayed again as FDA extends clinical hold review while labeling issues emerge for the motion sickness treatment.
Pharma Stock Moves: Oppenheimer Downgrades Rhythm, New Buys on Vanda, Verrica, CervoMed, and Ventyx
Oppenheimer downgrades Rhythm Pharmaceuticals after major gains, while analysts issue fresh Buy ratings on Vanda, Verrica, CervoMed, and Ventyx highlighting key catalysts and growth potential.